Vishria Bird Financial Group LLC Invests $350,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Vishria Bird Financial Group LLC bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 41,792 shares of the company's stock, valued at approximately $350,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Amundi acquired a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at about $256,000. Principal Financial Group Inc. lifted its holdings in Amneal Pharmaceuticals by 9.3% during the 4th quarter. Principal Financial Group Inc. now owns 96,835 shares of the company's stock worth $767,000 after buying an additional 8,213 shares in the last quarter. Handelsbanken Fonder AB bought a new position in Amneal Pharmaceuticals in the fourth quarter valued at about $309,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Amneal Pharmaceuticals by 45.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company's stock worth $2,522,000 after buying an additional 99,866 shares during the period. Finally, California State Teachers Retirement System lifted its stake in shares of Amneal Pharmaceuticals by 10.3% in the 4th quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock valued at $1,043,000 after purchasing an additional 12,282 shares during the period. Institutional investors and hedge funds own 31.82% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on AMRX. The Goldman Sachs Group assumed coverage on Amneal Pharmaceuticals in a report on Friday, June 6th. They set a "buy" rating and a $12.00 target price on the stock. Wall Street Zen cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $11.60.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX traded up $0.16 during trading on Wednesday, hitting $8.37. 1,525,213 shares of the company traded hands, compared to its average volume of 1,456,753. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of -209.20 and a beta of 1.06. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.32 and a fifty-two week high of $9.48. The business's fifty day moving average is $7.61 and its 200 day moving average is $7.91.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Friday, May 2nd. The company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 188.26% and a negative net margin of 0.46%. The company had revenue of $695.42 million during the quarter, compared to the consensus estimate of $714.78 million. On average, analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.